Zhang Guxiang, Yu Jiajing, Pei Zhiqiang, Xie Fei, Ding Ruiyang, Bao Lili, Li Anyang
Department of Respiratory & Critical Care Medicine, Affiliated Hospital of West Anhui Health Vocational College, Lu'an City, Anhui Province, China.
Department of Rheumatology & Immunology, Lu'an People's Hospital of Anhui Province, Lu'an City, Anhui Province, China.
Clinics (Sao Paulo). 2025 Jan 28;80:100563. doi: 10.1016/j.clinsp.2024.100563. eCollection 2025.
To evaluate the efficacy and safety of pulmonary rehabilitation under the supervision of health professionals at the institute versus conventional exercise-based pulmonary rehabilitation at home in Chronic Obstructive Pulmonary Disease (COPD) patients.
Patients of COPD received pulmonary rehabilitation under the supervision of a professional at the institute (PI cohort, n = 115) or self-driven traditional Chinese methods-based pulmonary rehabilitation at home (CE cohort, n = 127) or did not receive any type of pulmonary rehabilitation (ME cohort, n = 155). All patients received inhaled pharmacological treatment for COPD.
Before commencing inhaled pharmacological treatment with or without pulmonary rehabilitation (BT) COPD patients had 5 (5-4) / patient BODE (body-mass index, airflow obstruction, dyspnea, and exercise capacity) index score and 12 (13-12) / patient exacerbations (in 6-months) reported. After 6 months of inhaled pharmacological treatment for COPD with or without pulmonary rehabilitation (AT), a six-minute walking test was improved and the BODE index score and exacerbations during 6 months were decreased for patients of the PI cohort as compared to BT conditions and compared to those of the CE and ME cohorts in AT conditions (p < 0.05 for all). Patients of PI, CE, and ME cohorts had the risk of under treatment for <0.01 BODE index score, <1.32 BODE index score, and <3.14 BODE index score, respectively.
Chinese patients with COPD have worse clinical conditions. After 6 months of inhaled pharmacological treatment for COPD with pulmonary rehabilitations at institutes improves the conditions of COPD patients.
评估在该机构健康专业人员监督下的肺康复与慢性阻塞性肺疾病（COPD）患者在家中进行的传统运动型肺康复的疗效和安全性。
COPD患者在该机构专业人员监督下接受肺康复（PI队列，n = 115），或在家中接受基于传统中医方法的自主肺康复（CE队列，n = 127），或未接受任何类型的肺康复（ME队列，n = 155）。所有患者均接受COPD吸入药物治疗。
在开始使用或不使用肺康复的吸入药物治疗之前（BT），COPD患者的BODE（体重指数、气流阻塞、呼吸困难和运动能力）指数评分为5（5 - 4）/患者，且报告有12（13 - 12）/患者（6个月内）病情加重。在进行6个月的使用或不使用肺康复的COPD吸入药物治疗之后（AT），与BT情况相比，PI队列患者的六分钟步行试验有所改善，且在AT情况下，与CE和ME队列患者相比，PI队列患者的BODE指数评分和6个月内病情加重情况有所减少（所有p < 0.05）。PI、CE和ME队列患者分别在BODE指数评分<0.01、<1.32和<3.14时有治疗不足的风险。
中国COPD患者的临床状况较差。在机构进行肺康复并进行6个月的COPD吸入药物治疗后可改善COPD患者的状况。
